Site Map
Pages
- About Clinical Trials
- Alex Bruni
- Andrew Cunningham, PhD
- Angela Galindo
- Blog
- Brian Slack
- Careers
- Chris Martin
- Chris Takimoto, MD, PhD
- Company
- Company Sample
- Contact
- Cookie Policy
- Craig Sowell
- David Diamond
- Dr Austin Duffy, MB
- Dr Agustin Penedo, MD
- Dr Amita Patnaik
- Dr André Mansinho, MD
- Dr Andrew Sochacki, MD
- Dr Bernard Doger, MD, PhD
- Dr Daniel Morillo, MD
- Dr Drew W. Rasco, MD
- Dr Emiliano Calvo, MD, PhD
- Dr Gala Vega, MD
- Dr Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
- Dr Irene Moreno, MD
- Dr Justin A. Call, MD
- Dr Kyriakos P. Papadopoulos
- Dr Leigh M. Seamon, DO, MPH, FACOG, FACS
- Dr Manish R. Sharma, MD
- Dr Manuel Pedregal, MD
- Dr Maria De Miguel, MD, PhD
- Dr Muralidhar Beeram, MD, MBBS
- Dr Nehal J. Lakhani, MD, PhD
- Dr Roberto Martin, MD
- Dr Sreenivasa R. Chandana, MD, PhD
- Dr Tatiana Hernández Guerrero, MD, PhD
- Dr Victor Moreno, MD, PhD
- Dr William B. McKean, MD, PhD
- Early Phase
- Emmanuel Olart
- Etn Category
- Etn Speaker Category
- Etn Tags
- Events
- Explore Clinical Trials
- Heather Kobbe, MHA, SHRM-SCP
- Home
- Hospitals & Oncology Practices
- James Petkun
- Josh Jacobson
- Joshua Crawford
- Kathryn Britton
- Katie Celentino, DNP, RN, CMSRN
- Lauren Panco
- Leadership
- Lindsay Belcher, MBA
- Locations
- Message from the CEO
- Mike Wick
- Newsroom
- Nick Slack, MBE
- Patient Stories
- Pharma
- Preclinical
- Preclinical TEST
- Press
- Principal Investigators
- Privacy Policy
- Products
- Publications
- Referring Physicians
- Research & Development
- Ryan Carpentier
- Sandi Tevelow
- Site Map
- START – Barcelona
- START – Carolinas
- START – Dublin
- START – Lisbon
- START – Madrid – CIOCC
- START – Madrid – FJD
- START – Midwest
- START – Mountain Region
- START – Rioja
- START – San Antonio
- Webinars
Posts
- William B. McKean, MD, PhD
- Why Moving More Cancer Trials Into the Community Benefits Patients and Sponsors
- Why Adaptive Clinical Trials in Community Settings are the Future of Cancer Research
- Wearable Technology in Early-Phase Cancer Trials: Advancing Objective Performance Measures
- Victor Moreno, MD, PhD
- Together in the Fight Against Cancer: Thomas’ Story of Community and Care
- The Undruggable Cancer Target: KRAS Inhibitors Move Ahead in the Clinic
- The START Center for Cancer Research Takes a Major Step Forward in its Mission to Bring the Hope of Cancer Research to Communities Globally
- The START Center for Cancer Research Expands its Capabilities to Support Early-Phase Hematological Cancer Trials
- The START Center for Cancer Research Appoints Dr. Chris Takimoto as Chief Medical Officer
- The START Center for Cancer Research and Fundación Rioja Salud Announce New Partnership to Further Expand Access to Early Phase Clinical Trials in Spain
- The Connection Between Young Adults and Colon Cancer
- Tatiana Hernández Guerrero, MD, PhD
- Targeted Therapies for Cancer, Insights from Dr. María de Miguel
- T-cell–engaging Therapy for Solid Tumors
- T cell engagers in solid tumors kick the door down
- START’s Amita Patnaik, MD, FRCPC: One of PharmaVoice’s 100 Most Inspiring Leaders of 2024
- START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center
- START Dublin – the need, the science, and the pure serendipity of it all
- START Center to Open Lisbon, Portugal Location
- START Center Principal Investigators Contributed As Authors to 10 Posters and Abstracts at the Annual ESMO IO Meeting
- START Center for Cancer Care to Open New Locations in Lisbon and Dublin
- START Announces Launch of Virtual Panel Series: “The Power of Community Site Networks: Advancing Science & Broadening Access to Early Phase Cancer Trials”
- Sreenivasa R. Chandana, MD, PhD
- SITC 2025
- Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRASG12C Mutation
- SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
- Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)
- Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
- SABCS 2025
- Roberto Martin, MD
- Robert Jansen, MD
- Richard Young, MD, FACS
- Redefining Colorectal Cancer Research: Real-World Insights from Oncology Experts
- Ramon Yarza, MD, MBI, MSc
- Predictive and therapeutic implications of a novel PLCy1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer
- Precision Oncology: Tailoring Treatments for Better Outcomes
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
- Pembrolizumab for the treatment of non-small-cell lung cancer
- Patient-specific comorbidities as prognostic variables for survival in myelofibrosis
- Overcoming Resistance: Enhancing CDK4/6 Inhibitor Efficacy in Advanced Breast Cancer Treatment
- Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor
- Northwell Health and The START Center for Cancer Research to Form Strategic Partnership, Increasing Patient Access to Breakthrough Cancer Research
- NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
- New Location Test
- New designs in early clinical drug development
- New Clinical Trial Unit Opens for Irish Cancer Patients
- Nehal J. Lakhani, MD, PhD
- Neal D. Shore, MD, FACS
- Navigating Cohort Management in Early Phase Oncology Trials
- Muralidhar Beeram, MD, MBBS
- MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor
- María de Miguel, MD, PhD, MBA
- Manuel Pedregal, MD, MSc
- Manish R. Sharma, MD
- Malignant Hematology: Advancing Treatment in Blood Cancers
- Leigh M. Seamon, DO, MPH, FACOG, FACS
- Leading the Charge in Early Phase Oncology Trials: START’s Impact at the ASCO 2024 Annual Meeting
- Kyriakos P. Papadopoulos, MD
- Justin A. Call, MD
- Juan Jose Soto, MD, MSc
- Jessica Swaim, MD
- Jacquelyn Booher, DO
- Irene Moreno, MD
- Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
- Increased vulnerability of clinical research units during the COVID-19 crisis and their protection
- Improving Access to Phase 1 Cell & Gene Therapy Trials in Europe: Perspectives from Dr. Victor Moreno
- Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study
- Hope in His Backyard: Rickie’s Cancer Journey with START
- Histology-agnostic drugs: A paradigm shift – A narrative review
- HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome
- Hematology Test
- Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
- Gala Vega, MD
- First-in-human study with preclinical data of Bcl-2/Bcl-XL inhibitor Pelcitoclax in locally advanced or metastatic solid tumors
- First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
- First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
- First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
- First-in human, First-in-class Phase I Trial of the Anti-CD47 Antibody Hu5F9 G4 in Patients with Advanced Cancers
- First Patient Dosed with NILK-2401 in Phase I Clinical Trial
- First Patient Dosed with NILK-2301 in Phase I Clinical Trial
- First Dedicated Early Phase Oncology Clinical Trials Unit in Ireland opened by Minister Donohoe at the Mater Hospital
- Finding Hope with Clinical Trials: Q&A with Nick Slack
- Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase I Trial Evaluating XL102 in Patients with Advanced Solid Tumors
- Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumors (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
- Ester García-Lorenzo, MD
- ESMO Congress 2025
- Enabling Successful Sites Ep. 3: Taking the Complexity Out of Oncology Trials
- Emiliano Calvo, MD, PhD
- EMBARK: Real-World Practical Tips for Using Enzalutamide for High-Risk Biochemical Recurrence
- EHA 2025 Congress
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- Early Exposure & Site Network Support Enable PI’s Enduring Interest in Research
- Driving Oncology Research Progress Through Access to Early-Phase Trials
- Drew W. Rasco, MD
- Dr. Victor Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors
- Dr. Patnaik shares her perspectives on START’s pivotal role in the development of new cancer drugs
- Dr. Maria de Miguel Analyzes the Future of ADCs in Oncology
- Dr. Emiliano Calvo Leads the Discussion of Next Generation Immunotherapy at ASCO 2023
- DPHARM 2025
- DPharm 2024: Problem Solving in the Clinical Trial Realm
- Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
- David Rich, MD
- Daniel Morillo, MD
- Damian Cubillas, MD
- Crystal structure of Spot 14, a modulator of fatty acid synthesis
- Community-Based Clinical Trials: A Catalyst for Advancing Targeted Therapies
- Combination Immunotherapy With IDO Inhibitors: Defining a Future Through Biomarker-Guided Patient Selection
- Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer
- Clinical Trials in Community Settings: How Do We Improve Participation?
- Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors
- Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent,2-methoxyestradiol
- CEO of START Reinforces the Importance of the Santa Maria Phase 1 Oncology Trial Center
- CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies
- Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models
- Brian Roberts, MD, FACS
- Breaking Barriers in Blood Cancer Treatment: Insights on the Future of Malignant Hematology
- Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
- Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341, a First-in-Class, Dual Bifunctional Degrader of CDK4/6, as a Monotherapy and in Combination with Fulvestrant for HR+/HER2- Breast Cancer
- Bernard Doger de Speville, MD, PhD
- Austin Duffy, MB, DMed
- Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
- Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy
- ASH Annual Meeting 2025
- ASCO Annual Meeting 2025
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Andrew Sochacki, MD
- André Mansinho, MD, MSc
- An Interview with Dr. Drew Rasco: The Basics of Phase I Clinical Trials
- An analysis of genetic targets for guiding clinical management of follicular lymphoma
- Amita Patnaik, MD, FRCPC
- After Wife Dies from Non-Smoking Lung Cancer, Utah Man Urges All to Test for Radon
- Advocating for Patient Access with Amita Patnaik, MD, FRCPC
- Advancing ADC Development: Expert Panel Explores Current Landscape and Future Opportunities
- ADCs: Targeted Therapeutics in the Modern Age
- Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
- Abhishek Srivastava, MD
- AACR Annual Meeting 2025
- A time to build and a time to burn: glucose metabolism for every season.
- A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors
- A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart® Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies
- A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
- A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
- A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (PODIUM-101)
- A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- ‘I Had No Lesions On My Skin. It Happens in 5pc of Cases’ – Dublin Woman Reached Stage Four Cancer Before Getting Access to Therapy
- ‘A Day of Hope’: Irish Hospital Patients Get Access to ‘Early Phase’ Cancer Drugs
